The Latest Breaking News from FDA

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

Donald Trump plans to skip testifying for a second time in the New York civil fraud trial. The FDA has approved the first-ever gene-editing treatment for a human disease.

Ministers are spending £290m of taxpayers’ money on a scheme that is yet to deliver. It’s our job as public servants to point out flaws in their plans, says Dave Penman, general secretary of the FDA union

From gonorrhea and syphilis to newer ailments, these are the STDs that you need to be on the watch for

Code found in the Fitbit app suggests that it might soon be able to work with the Pixel 8 Pro's built-in thermometer.

The U.S. Food and Drug Administration on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

The FDA approved two new therapies for sickle-cell disease, including the world's first-ever approved CRISPR therapy.

The announcement comes after the FDA became aware of more than 40 cases of "DRESS syndrome" linked to the seizure medications levetiracetam and clobazam.

The Food and Drug Administration approved two genetic treatments for sickle cell disease, including one that uses gene-editing. The approvals offer hope for patients and signal a new medical era.

Big money brings tough competition, and businesses can try all sorts of tactics to get an edge. The post “No Such Thing As Organic Honey”: 50 People Share Food Industry Secrets first appeared on Bored Panda.

House lawmakers are demanding information on federal efforts to stop the influx of kid-appealing electronic cigarettes from China